May Patients Receiving 5-Alpha-Reductase Inhibitors Be at Higher Risk of COVID-19 Complications?
April 2020
in “
Medical hypotheses
”
Studysummary This study proposes that the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia may contribute to poorer COVID-19 prognosis in males.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document hypothesized that 5-alpha-reductase inhibitors, used for treating benign prostatic hyperplasia (BPH), might contribute to poorer COVID-19 outcomes in males. This was based on the observation that males had a 65% higher mortality rate from COVID-19 compared to females. The inhibitors, such as finasteride and dutasteride, could disrupt androgen metabolism in the lungs, potentially impairing lung regeneration and surfactant production, which are crucial for recovery from severe COVID-19-related pneumonia. The hypothesis suggested that patients on these medications might be at higher risk for severe COVID-19 complications, warranting further interdisciplinary research to optimize treatment protocols.
